Standard Article

Cardiovascular gene therapy

Part 1. Genetics

1.7. Gene Therapy

Specialist Review

  1. Shalini Bhardwaj,
  2. Himadri Roy,
  3. Seppo Ylä-Herttuala

Published Online: 15 JAN 2005

DOI: 10.1002/047001153X.g107216

Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics

Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics

How to Cite

Bhardwaj, S., Roy, H. and Ylä-Herttuala, S. 2005. Cardiovascular gene therapy. Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics. 1:1.7:94.

Author Information

  1. University of Kuopio, Kuopio, Finland

Publication History

  1. Published Online: 15 JAN 2005


A variety of treatment modalities are presently available for the treatment of cardiovascular diseases either in the form of drug therapy or surgical intervention. A relatively new field of gene therapy for cardiovascular diseases is fast evolving. The diseases in focus are atherosclerosis, coronary and peripheral arterial diseases, coronary restenosis, and vein graft diseases. Promising results have been obtained in animal models of restenosis and vein graft thickening with transfer of genes encoding VEGF, nitric oxide synthatase, thymidine kinase, tissue inhibitors of metalloproteinases, and antisense oligonucleotides against transcription factors or cell cycle regulatory proteins. VEGF and FGF gene transfer have been successfully used in improving blood flow and development of collateral arteries in peripheral vascular disease and myocardial ischemic conditions. Here, we present a synopsis of the potential treatment genes, their therapeutic targets, mode of delivery, human clinical trials, and limitations encountered in the field of cardiovascular gene therapy.


  • angiogenic factors;
  • gene therapy;
  • restenosis;
  • ischemia